Sight Sciences Analyst Ratings
Sight Sciences (SGHT) Receives a Hold From Piper Sandler
Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)
Needham Remains a Hold on Sight Sciences (SGHT)
Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Integer Holdings (ITGR) and Pacific Biosciences (PACB)
Needham Remains a Hold on Sight Sciences (SGHT)
Needham Remains a Hold on Sight Sciences (SGHT)
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Raises Price Target to $4
Sight Sciences Analyst Ratings
Reevaluation of Sight Sciences' Financial Performance Amid Q3 Results and Reimbursement Uncertainty: A Hold Rating and Lowered Price Target
Stifel Nicolaus Remains a Buy on Sight Sciences (SGHT)
Sight Sciences Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Sight Sciences (SGHT)
Piper Sandler Reaffirms Their Hold Rating on Sight Sciences (SGHT)
Sight Sciences Analyst Ratings
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $4
Sight Sciences Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Sight Sciences, Lowers Price Target to $4
Sight Sciences Analyst Ratings
Piper Sandler Cuts Sight Sciences to Neutral, Cites Lowered Guidance
No Data